SISRAM MED's unaudited revenue for the third quarter achieved double-digit year-on-year growth and will orderly advance the commercialization process of Daxifei in mainland China
I'm PortAI, I can summarize articles.
SISRAM MED achieved double-digit year-on-year growth in unaudited revenue in the third quarter of 2025, mainly due to strong performance in the markets of China, South Korea, and Thailand. The group will continue to drive the penetration of the Soprano series in the Asia-Pacific region and accelerate the commercial deployment of Universkin by Alma in the U.S. market, while orderly advancing the commercialization process of Daxifei in mainland China
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments